Biocon Expects ‘Successful’ US Trastuzumab Launch Despite Amgen Debut
India’s Biocon reported first-quarter net profit that soared by more than 70% and said it was confident of a “very successful” US trastuzumab launch, despite rival Amgen stealing a march by commercializing its own biosimilar first in the world’s largest drug market.
You may also be interested in...
Biocon has joined the march of Indian firms into China, tying up with Chinese firm CMS to sell three generic formulations in the world’s second-largest drug market.
Genentech has been denied its request for a US injunction against Amgen over its at-risk launch of a trastuzumab biosimilar rival to Herceptin.
Amgen has launched its Kanjinti biosimilar version of trastuzumab in the US after a court refused Genentech’s request for an injunction. At the same time, Amgen has also introduced its Mvasi bevacizumab biosimilar. The launches represent Amgen’s first biosimilar introductions in the US.